Exchange & Returns Information
Review Details
(0)
| Generic For | VERZENIO |
|---|---|
| Active Ingredient | ABEMACICLIB |
| Strength | 150MG |
| Manufacturer | ELI LILLY AND COMPANY |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 14 TABLETS | $ 35.47 | $ 496.60 |
$ 422.11
Apply ZARVY26 (-15%)
You save $ 74.49
|
||
| 2 BOXES - 28 TABLETS | $ 35.19 |
1% $ 993.20
$ 985.20
|
$ 837.42
Apply ZARVY26 (-15%)
You save $ 147.78
|
||
| ★ Best Value 3 BOXES - 42 TABLETS | $ 35.09 |
1% $ 1,489.80
$ 1,473.80
|
$ 1,252.73
Apply ZARVY26 (-15%)
You save $ 221.07
|
Reference information will be available soon.
Ramiven 150 is a generic formulation of abemaciclib 150mg, an oral CDK4/6 inhibitor indicated for the treatment of hormone receptor-positive (HR+), HER2-negative breast cancer. By inhibiting cyclin-dependent kinases 4 and 6, it disrupts cell cycle progression from the G1 to S phase, thereby preventing tumor cell proliferation.
Unlike other agents in its class, Ramiven 150 is notable for being the only CDK4/6 inhibitor approved as monotherapy in specific advanced breast cancer settings. Additionally, it is approved for 2-year adjuvant therapy in early-stage breast cancer, expanding its role beyond metastatic disease into curative-intent treatment strategies.
AntiCancer Drugs > Hormone Receptor Positive, HER2 Negative Breast Cancer
Used in combination with endocrine therapy for advanced or metastatic HR+/HER2- breast cancer. Demonstrates significant benefit in delaying disease progression and improving overall survival.
AntiCancer Drugs > Early Stage Breast Cancer
Approved as an adjuvant treatment to lower the risk of recurrence in patients with high-risk HR+/HER2- early breast cancer. Particularly effective in node-positive cases when administered for up to 2 years.
AntiCancer Drugs > Off-label Solid Tumors
Under investigation for use in lung, head and neck, gastrointestinal, and other solid tumors characterized by CDK pathway dysregulation or chemotherapy resistance, expanding its potential role beyond breast cancer.
Abemaciclib 150mg functions as a CDK4/6 enzyme inhibitor, blocking the transition from the G1 to S phase of the cell cycle. By preventing DNA replication, it effectively suppresses tumor cell proliferation.
Unlike other CDK4/6 inhibitors, it provides continuous target inhibition, which contributes to its sustained antitumor activity. This makes it effective in both combination regimens with endocrine therapy and as monotherapy in selected breast cancer settings.
Early Breast Cancer (Adjuvant):
→ 150 mg orally twice daily
→ Administer with tamoxifen or an aromatase inhibitor
→ Continue for up to 2 years or until recurrence or unacceptable toxicity
Advanced or Metastatic Breast Cancer:
→ 150 mg orally twice daily with fulvestrant or an aromatase inhibitor
→ 200 mg orally twice daily as monotherapy
→ Continue until disease progression or unacceptable toxicity
Dosing Notes:
→ May be taken with or without food
→ Swallow tablets whole; do not crush or split
→ Use GnRH agonist in premenopausal patients receiving AI or fulvestrant
→ Monitor for neutropenia, liver enzyme elevations, and diarrhea
Store below 30°C in the original container
Protect from moisture and direct light
Keep out of reach of children
Common: diarrhea, fatigue, nausea, decreased appetite, abdominal pain, neutropenia
Less common: elevated liver enzymes, infections, thromboembolic events, anemia, alopecia
Seek medical help for persistent diarrhea, fever, or signs of liver toxicity
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
